Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis
- 31 March 2022
- journal article
- research article
- Published by Elsevier in Dermatologic Clinics
- Vol. 40 (2) , 137-143
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysisAllergy, 2020
- A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyJournal of the European Academy of Dermatology and Venereology, 2020
- Health care regulation, the Food and Drug Administration (FDA), and access to medicineJournal of the American Academy of Dermatology, 2020
- Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective reviewJournal of the American Academy of Dermatology, 2020
- Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulationsArthritis Research & Therapy, 2019
- Association of Atopic Dermatitis With Sleep Quality in ChildrenJAMA Pediatrics, 2019
- Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitisPediatric Dermatology, 2019
- Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscapeAnnals of Allergy, Asthma & Immunology, 2018
- Anti–Interleukin-31 Receptor A Antibody for Atopic DermatitisNew England Journal of Medicine, 2017
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014